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Aurora kinases play critical roles in regulating spindle assembly, chromosome segregation, 
and cytokinesis to ensure faithful segregation of chromosomes during mitotic cell division 
cycle. Molecular and cell biological studies have revealed that Aurora kinases, at physiological 
levels, orchestrate complex sequential cellular processes at distinct subcellular locations 
through functional interactions with its various substrates. Aberrant expression of Aurora 
kinases, on the other hand, cause defects in mitotic spindle assembly, checkpoint response 
activation, and chromosome segregation leading to chromosomal instability. Elevated 
expression of Aurora kinases correlating with chromosomal instability is frequently detected 
in human cancers. Recent genomic profiling of about 3000 human cancer tissue specimens 
to identify various oncogenic signatures in The Cancer Genome Atlas project has reported 
that recurrent amplification and overexpression of Aurora kinase-A characterize distinct 
subsets of human tumors across multiple cancer types. Besides the well-characterized 
canonical pathway interactions of Aurora kinases in regulating assembly of the mitotic 
apparatus and chromosome segregation, growing evidence also supports the notion that 
deregulated expression of Aurora kinases in non-canonical pathways drive transformation 
and genomic instability by antagonizing tumor suppressor and exacerbating oncogenic 
signaling through direct interactions with critical proteins. Aberrant expression of the Aurora 
kinases–p53 protein family signaling axes appears to be critical in the abrogation of p53 
protein family mediated tumor suppressor pathways frequently deregulated during oncogenic 
transformation process. Recent findings reveal the existence of feedback regulatory loops in 
mRNA expression and protein stability of these protein families and their consequences on 
downstream effectors involved in diverse physiological functions, such as mitotic progression, 
checkpoint response pathways, as well as self-renewal and pluripotency in embryonic stem 
cells. While these investigations have focused on the functional consequences of Aurora 
kinase protein family interactions with wild-type p53 family proteins, those involving Aurora 
kinases and mutant p53 remain to be elucidated. This article presents a comprehensive 
review of studies on Aurora kinases–p53 protein family interactions along with a prospective 
view on the possible functional consequences of Aurora kinase–mutant p53 signaling 
pathways in tumor cells. Additionally, we also discuss therapeutic implications of these 
findings in Aurora kinases overexpressing subsets of human tumors.
Keywords: Aurora kinases, p53 tumor suppressor protein family, chromosome instability, centrosome 
amplification, pluripotency, tumorigenesis
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iNTRODUCTiON
Gain-of-function alterations in the Aurora kinase protein family 
member, Aurora kinase-A (AURKA), due to amplification and/
or overexpression of the gene- and loss-of-function changes 
in the TP53 tumor suppressor protein have been associated 
with multiple cellular phenotypes of similar nature, such as 
centrosome amplification, override of spindle assembly, and 
DNA damage checkpoint response, aneuploidy, and cellular 
transformation. Induction of such shared cellular phenotypes 
consequent to AURKA overexpression or functional inactiva-
tion of TP53 as well as reported localization of the two proteins 
at the centrosomes indicate that AURKA and TP53 (hereafter 
referred to as Aurora-A and p53) are involved in overlapping 
signaling pathways regulating the abovementioned cancer-
associated aberrant cellular phenotypes through direct or indi-
rect functional interactions (1–5). Evidence in support of this 
concept first became available following demonstration that p53 
could suppress Aurora-A’s oncogenic potential through physi-
ological interaction in transactivation-independent manner 
in mammalian cells (6). Similarly, Xenopus p53 was shown to 
inhibit Aurora-A kinase activity, indicating that the inhibitory 
role of p53 on Aurora-A kinase enzyme activity is conserved 
among vertebrates (7). Later studies have revealed that p53, 
besides inhibiting the kinase activity of Aurora-A through direct 
interaction, also regulates Aurora-A function in transactivation-
dependent manner, as discussed below.
In addition to the findings mentioned above, a number of 
studies have identified Aurora kinases regulating p53 function 
through phosphorylation-mediated posttranslational modifica-
tion of either p53 protein directly or a p53 interacting protein 
at multiple residues with each phosphorylation event having 
distinct functional consequence. Aurora-A phosphorylates p53 
at serine 315, facilitating MDM2-mediated p53 ubiquitination 
and degradation (8), whereas phosphorylation of serine 215 
inhibits p53 DNA-binding and transactivation function (9). 
These findings demonstrated that Aurora-A phosphorylation 
of p53 negatively regulates p53 tumor suppressor functions, 
resulting in abrogation of DNA damage checkpoint and induc-
tion of cell death responses in Aurora-A overexpressing cells. 
As a consequence, Aurora-A overexpressing cancer cells with 
wild-type p53 acquire cellular phenotypes associated with p53 
loss-of-function mutant harboring cancer cells. A more recent 
finding of a novel Aurora-A phosphorylation residue, serine 106 
of p53, was, however, reported to have an opposing effect on p53 
stability compared with the destabilization effect of Aurora-A-
mediated phosphorylation of p53 at serine 315. Phosphorylation 
of p53 serine 106 was shown to inhibit the interaction of p53 
with MDM2 and prolong the half-life of p53 protein (10). 
Physiological significance of Aurora-A-mediated p53 phospho-
rylation at serine 106 in vivo and its functional implications in 
Aurora-A overexpressing tumor cells remain unknown. The 
possibility of enhanced p53 protein stability in Aurora-A overex-
pressing tumor cells appears intriguing since steady-state levels 
of Aurora-A and p53 proteins have been reported to be inversely 
correlated in most human tumors. Molecular characterization 
studies have shown that serine 215 phosphorylation is associated 
with loss of serine 33 phosphorylation of p53, mediated by p38 
critical for p53 activation stabilization and induction of apop-
tosis, indicating that Aurora-A mediates cross-talk between 
N- and C-terminal posttranslational modifications of p53 (11, 
12). In addition, Aurora-A also indirectly compromises p53 
function by phosphorylating positive and negative regulators of 
p53, such as hnRNPK and MDM2 proteins, respectively. The 
RNA-binding protein, such as hnRNPK, is a p53 transcriptional 
cofactor that promotes gene expression in response to DNA 
damage and is also a target of MDM2 (13, 14). While Aurora-
A-mediated hnRNPK phosphorylation at serine 379 disrupts its 
interaction with p53 and impairs DNA damage-induced gene 
expression, MDM2 phosphorylation at serine 166 enhances 
its protein stability and in turn destabilizes p53 (15–17). These 
findings demonstrate that Aurora-A is involved in regulating 
p53 downstream signaling negatively affecting growth arrest 
and apoptotic response pathways.
Aurora-B has also been shown to interact with and phospho-
rylate p53 at multiple residues in DNA-binding domain. Similar 
to the effect of Aurora-A phosphorylation on p53 activity and 
stability, Aurora-B phosphorylations of p53 at serine 269 and 
threonine 284 inhibit p53 transactivation activity, whereas 
phosphorylations at serine 183, threonine 211, and serine 215 
accelerate the degradation of p53 through polyubiquitination-
mediated proteasome pathway (18, 19). However, these studies 
have been performed with phosphor mutants of p53 under con-
ditions of ectopic expression in cells and thus physiological rel-
evance of identical in vivo phosphorylations have not been well 
validated. Further investigations of endogenous protein modifi-
cations are required to verify the role of Aurora-B-mediated p53 
phosphorylations in vivo and to determine how Aurora-A and 
Aurora-B may be coordinately regulating p53 function through 
the cell cycle. It is worth noting that exogenously expressed p53 
colocalizes with Aurora-B at centromeres during mitosis. This 
observation may be biologically significant since several spindle 
assembly checkpoint (SAC) kinases such as MPS1/TTK, BUB1, 
and BUBR1, localized at kinetochores, have been reported to 
functionally interact with p53 in activating spindle assembly 
and postmitotic checkpoint response pathways (20–23). In 
view of these findings and those demonstrating Aurora kinases 
regulating functions of p53 family proteins, it is likely that vary-
ing levels of Aurora kinases in tumor cells influence the extent 
of deregulations in checkpoint response pathway activation 
downstream of p53 family proteins in tumor cells. We discuss 
the role of Aurora kinases–p53 protein family signaling axis in 
SAC response pathway later in this review.
Aurora-A involvement in regulating p73 function first 
became evident from a study in which Aurora-A inhibitor treat-
ment or knockdown of Aurora-A in p53-deficient cells induced 
p73-mediated expression of apoptosis-related genes and also 
cell death (16). Further investigation revealed that Aurora-A 
directly interacts with and phosphorylates p73 at serine 235 in 
the DNA-binding domain, an equivalent site of serine 215 in 
p53, resulting in loss of its DNA-binding and transactivation 
activity. As a result, cells become resistant to DNA damage-
induced cell death (24). Importantly, this study uncovered 
that Aurora-A phosphorylation of p73 leads to the formation 
FigURe 1 | Proteins interacting with Aurora-A, Aurora-B, p53, and 
p73. Venn diagram showing the number of shared and unique proteins 
interacting with Aurora-A, Aurora-B, p53, and p73. Protein–protein interaction 
data were downloaded from the BioGRID (v3.4) and STRING (v9.1) 
databases.
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of a large molecular complex that includes the chaperon pro-
tein Mortalin promoting translocation of the Mortalin–p73 
complex into cytoplasm. Similar cytoplasmic distribution of 
Aurora-A phosphorylated p53 at serine 215 in a complex with 
Mortalin was observed as well. As a corollary to this finding, 
cytoplasmic distribution of p73 was found to correlate with 
Aurora-A expression levels in human primary pancreatic cancer 
tissues. Moreover, consistent with the earlier findings that p73 
deficiency causes relaxation of the SAC reflected in the mislo-
calization of BUB1 and BUBR1 at kinetochores and reduced 
BUBR1 kinase activity (25–27), Aurora-A phosphorylation of 
p73 in a constitutive manner was found to facilitate accelerated 
mitotic progression and exit accompanied with relaxation of 
SAC due to premature dissociation of the MAD2–CDC20 
complex in proliferating cells in  vitro. SAC inactivation cor-
related with significant increase in multinucleated cells. These 
findings indicate that the mitotic checkpoint functions of p53 
family proteins are regulated in a complex manner involving 
Aurora kinase-mediated posttranslational modifications dur-
ing mitotic progression. It is currently unknown whether p73 
reciprocally controls Aurora-A kinase function and if Aurora-B 
and Aurora-C also regulate p73 function.
Along with the discovery of crosstalk between Aurora kinases 
and p53 family proteins, there is growing evidence that these 
protein complexes directly or indirectly participate in various 
cellular processes and inappropriate activation of Aurora kinases 
can have dominant-negative effects on the phenotypes of normal 
cells involving pathways regulated by a variety of proteins func-
tionally interacting with p53 protein family (Figure 1; Table 1). 
In the following sections, we summarize the current knowledge 
of Aurora kinases–p53 protein family signaling cascades relevant 
to the regulation of posttranslational modifications and stability 
of proteins, activity and integrity of centrosomes, checkpoint 
pathways in normal and aberrant mitosis, as well as protein–
protein interactions and transcription and translation of genes 
involved in the development of pluripotent embryonic stem cells 
(ESC) and cancer stem cells (CSC), as outlined in the schematic 
overview diagram in Figure 2.
MeCHANiSM OF DOwNRegULATiON OF 
AURORA KiNASeS BY p53
In addition to direct inhibition of Aurora-A by p53 via  protein–
protein interaction, p53 has been shown to downregulate 
Aurora-A expression, kinase activity and stability through its 
binding to Aurora-A promoter or transactivation of its target genes 
including p21, Gadd45a, and Fbxw7α. Genome-wide chromatin 
occupancy of p53 analyzed by chromatin immunoprecipitation-
seq (ChIP-seq) following activation with non-genotoxic mol-
ecules and genotoxic chemotherapeutic drugs revealed AURKA 
gene promoter as one of the novel p53 target sequences and that 
direct p53 binding to the promoter of AURKA gene repressed 
expression in MCF-7 and HCT-116 cells (28). This study also 
found that STAT3 binds to AURKA promoter and antagonizes 
p53-mediated repression of AURKA. Intriguingly, a recent study 
has shown that Aurora-A promotes STAT3 activity through regu-
lating expression and phosphorylation levels of JAK2 in gastric 
and esophageal cancers (29), indicating the existence of negative 
feedback regulation of p53 function by Aurora-A–JAK2–STAT3 
axis. These results suggest that the combination of Aurora-A 
and JAK2 inhibitors with p53 activators might be an effective 
therapeutic approach for the treatment of cancer. Both p21 
and Gadd45a are transcriptionally activated by p53 upon DNA 
damage and play important roles in DNA repair and cell cycle 
checkpoint response. The E2F family transcription factor, E2F3 
is known to be involved in the transactivation of Aurora-A gene 
expression during G2–M cell cycle progression (30). Induction of 
the cyclin-dependent kinase inhibitor, p21 leads to inhibition of 
Cdk kinase activity resulting in the maintenance of RB1 in hypo-
phosphorylated state in a complex with E2F3, thereby impairing 
activation of Aurora-A gene expression, an indirect downstream 
effect of p53–p21 signaling axis. It is noteworthy that Aurora-B 
phosphorylates RB1 at serine 780, a known inhibitory phospho-
rylation site for Cdk4. Thus, deregulation of Aurora-B might lead 
to Aurora-A overexpression through direct downregulation of 
both p53 and RB1 functions. In fact, co-occurrence of increased 
gene expression of both Aurora-A and Aurora-B is observed 
in some human tumors. On the other hand, Gadd45a inhibits 
Aurora-A kinase activity via direct interaction to prevent cells 
from Aurora-A-induced centrosome amplification and aborted 
cytokinesis (31). These results indicate that cooperative inhibition 
of Aurora-A activity by p53 and Gadd45a is important for cells 
to maintain centrosome number and chromosomal/genomic 
stability.
Besides regulating Aurora kinase function through tran-
scription-dependent and -independent mechanisms, p53 also 
downregulates Aurora-A activity by modulating its degradation 
pathway. Fbxw7α is a p53-dependent haploinsufficient tumor 
suppressor protein and a component of the SCF-like ubiquitin 
ligase complex that targets both Aurora-A and Aurora-B for 
proteasome degradation (32–34). Fbxw7α is frequently mutated 
or downregulated in tumors. Importantly, Fbxw7α cooperates 
with PTEN to regulate Aurora-A degradation via the PI3K/
AKT/GSK3β pathway and Fbxw7α also preferentially degrades 
active Aurora-A (33, 35). It has been demonstrated that Aurora-
A-mediated centrosome amplification and subsequent induction 
TABLe 1 | List of proteins interacting with Aurora–p53 family protein complex represented in venn diagram in Figure 1.
Combination Qty interacting proteins
AURKA/AURKB/p53/p73 31 ATM, BCL2, BIRC5, BRCA2, CCNA2, CCNB1, CCND1, CCNG1, CDC20, CDC25A, CDC25C, CDK1, CDK2, CDK4, CDKN1A, 
DDB1, GADD45A, HSPA9, LRPPRC, MTOR, MYL9, PCNA, PTEN, PTTG1, RASSF1, RPS27A, SUMO1, TP63, UBC, UBE2I, 
XPO1
AURKA/AURKB/p53 67 BARD1, BIRC6, BUB1, CDC14A, CDC14B, CDK5, CENPA, CEP55, DDX5, ECT2, FBXW7, FTH1, FZR1, HNRNPA1, HNRNPU, 
HSP90AA1, HSP90AB1, HSPA1A, HSPA5, IQGAP1, IRS4, MAP9, NCL, NFKBIA, NINL, NPM1, OFD1, PARP1, PBK, PLK1, 
PLK3, PPP1CA, PPP1CC, PPP3CA, PRRC2C, PSMB3, PSMC3, PSMC5, PSMD10, PSMD11, PSMD4, PSMD6, PSME3, 
RPS16, RPS27, RPS4X, RRM2, SETD1A, SMARCB1, TCEAL4, TK1, TOP2A, TOP2B, TP73, TTK, TUBA1A, TUBA1C, 
TUBA4A, TUBB, TUBB2A, TUBG1, UBA52, UBB, UBE2D1, UBE2N, YY1, YY2
AURKA/AURKB/p73 13 BUB1B, CCNA1, CHFR, E2F2, E2F3, FLT3, HIST1H3C, LATS2, MAD2L1, SASS6, TK2, TP53, TSPO
AURKA/p53/p73 23 AKT1, AURKB, CASP1, CDKN2A, CHUK, CSNK2A1, DICER1, EGFR, ESR1, GSK3B, HDAC2, HRAS, IGF2BP1, IKBKB, 
MDM2, MYC, NEDD8, PIK3CA, PML, RPL11, RPS19, TAF9, WWOX
AURKB/p53/p73 12 AURKA, BRCA1, CHEK1, CHEK2, DNMT1, EP300, EZH2, H2AFX, HDAC1, MAPK8, PPP1R13L, RB1
AURKA/p53 58 ALB, BTRC, CELA2B, CEP120, CEP128, CEP135, CEP152, CSNK1D, CSNK1E, DCAF7, DGCR14, EEF1A1, EEF2, HAUS1, 
HNRNPA2B1, HNRNPK, HSPA2, HSPA8, IGF2BP3, ITPKC, KLF4, KRAS, LYZ, MFAP4, MRPL24, MRPS22, NFKB1, NIN, 
NME1, NRAS, PCMT1, PDCD5, PDCD6, REL, RFC4, RPL12, RPL23, RPL27, RPL30, RPLP0, RPLP2, RPS10, RPS14, RPS3, 
RPS3A, RPS6, SETD2, SIRT7, SKP1, SRPK1, TFAP2A, TNRC6C, TRIM28, TUBB4B, VHL, YBX1, YWHAE, YWHAG
AURKB/p53 33 ABR, CCDC8, CUL7, DOCK7, DTL, GIGYF2, HDAC5, HDAC9, HERC2, MOGS, MRPS27, MYBBP1A, MYLK, NOC2L, PHKB, 
PRKDC, RANBP2, RAVER1, RPS25, SKP2, SMARCC1, SNW1, SUMO2, SUMO3, TBC1D4, TUBA8, UBR4, UBR5, UFD1L, 
VIM, VRK1, WEE1, ZWINT
AURKA/p73 9 AZI1, CCNE1, CDH13, CTNNB1, FUS, MYCN, OAZ1, PRKACA, PSRC1
AURKB/p73 8 ANKRD17, AURKC, CDKN1B, DSN1, GNB2L1, LATS1, STAG1, STK3
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of aneuploidy is mediated in part through dysfunction of p53–
Fbxw7α axis, commonly detected in human tumors and also in 
mouse models (33, 36). It is relevant in this context to mention 
that synthetic lethal screening of protein interacting with N-Myc 
in N-Myc amplified neuroblastoma has identified that Aurora-A 
stabilizes N-Myc by directing a K48 to K63/K11 switch in its 
ubiquitylation by Fbxw7α (37). Although this interaction was 
reported to be independent of Aurora-A kinase activity, recent 
finding have demonstrated that inhibitor of Aurora-A kinase 
activity can disrupt interaction between Aurora-A and Fbxw7α, 
leading to N-Myc destabilization and tumor regression in mouse 
model of N-Myc-driven neuroblastoma xenograft (38). Similarly, 
Aurora-B inhibitor treatment also showed profound growth inhi-
bition and tumor regression in N-Myc-driven neuroblastoma, 
although the underlying mechanism of this finding remains 
unclear (39, 40).
Recent studies have identified an important role of microRNA 
functional networks in the control of gene expression and pro-
tein stability of Aurora-A and Myc involving the p53–Fbxw7α 
axis in neuroblastoma and other tumors. A well-characterized 
tumor suppressor micoRNA, let-7, regulated by p53 directly 
targets Aurora-A, c-Myc, N-Myc, and RAN-binding protein 2 
(RANBP2). In normal cells, let-7-mediated suppression of c-Myc 
expression helps maintain basal low level expression of Aurora-A 
mRNA, while miR-25-targeted Fbxw7α regulates basal level 
protein expression (41–45). In p53-deficient and p53-mutant 
cells, these regulatory mechanisms are disrupted, and Aurora-A 
expression and stability are elevated. Functional genomic studies 
in N-Myc-amplified neuroblastoma have revealed that LIN28B 
RNA-binding protein promotes RAN level by directly binding 
to RAN mRNA and via RANBP2 by inhibiting let-7 expression, 
consequently facilitating Aurora-A activation and stabilization 
which in turn promote N-Myc stabilization (44). It was recently 
been reported that Aurora-A acts as a transactivating factor for 
hnRNPK, a known transcriptional cofactor of p53, to promote 
c-Myc expression and reciprocal c-Myc-mediated transactiva-
tion of Aurora-A gene in breast cancer stem-like cells (46). This 
finding on apparent absence of p53 inhibitory role in Aurora-
A–c-Myc positive regulatory circuit is associated with frequent 
observation of centrosome amplification in N-Myc-amplified 
neuroblastoma cells compared to non-amplified neuroblastoma 
cells. Mechanistically, N-Myc directly transactivates MDM2 and 
Aurora-A stabilizes MDM2 by phosphorylating at Ser-166 both 
of which impair p53 function, resulting in centrosome amplifi-
cation (17, 47, 48). Taken together, these data indicate that p53 
controls Aurora-A function through multiple inhibitory signal-
ing pathways and lack of p53 function results in deregulation of 
Aurora-A oncogenic signaling cascades which lead to profoundly 
aberrant phenotypes associated with tumor cells. Involvement 
of additional signaling pathways regulating centrosome activity 
and integrity mediated by Aurora-A–p53 interaction is discussed 
below.
iNvOLveMeNT OF AURORA-A–p53 
SigNALiNg PATHwAY iN CeNTROSOMe 
ACTiviTY AND iNTegRiTY
A common phenotypic change in cells with gain of Aurora-A 
and loss of p53 function is manifested in the form of increased 
FigURe 2 | Schematic overview diagram showing phenotypic consequences of physiologically regulated interactions in normal cells and 
deregulated interactions in cancer cells involving Aurora kinases–p53 protein family. CIN, chromosomal instability; ESC, embryonic stem cells; CSC, 
cancer stem cells.
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number of centrosomes. Multiple investigations have revealed 
that p53 controls centrosome duplication and separation in both 
transactivation activity-dependent and -independent manner 
(Figure  3). In transactivation activity-dependent mechanism, 
p21 expression plays a key role in synchronizing DNA replication 
and centrosome duplication by inhibiting Cdk2/Cyclin E activity 
which phosphorylates Nucleophosmin/NPM1 at centrosomes 
to promote its dissociation from the centrosomes to allow 
initiation of centrosome duplication (49). On the other hand, 
p53 downregulates PLK4 gene expression which is essential for 
centriole biogenesis through regulation of phosphorylations of 
centrosomal protein GCP6 and STIL (50–52).
In transactivation activity-independent mechanism, centro-
somal localization of p53 appears to be critical for negatively 
regulating centrosome biogenesis and its dissociation from 
centrosome appears to be sufficient to initiate centrosome 
duplication. p38–p53 axis was reported to play a central role 
in inhibition of G1–S cell cycle progression in response to loss 
of centrosome integrity. Centrosome perturbation caused by 
depletion of centrosomal proteins such as PCM1, centrobin, 
and TACC3 promotes the recruitment of both p38 and p53 
to centrosomes and facilitate p53 phosphorylation by p38 at 
serine 33, which in turn transduces the inhibitory signal for 
cell cycle arrest by inducing p21 expression (53–55). However, 
the precise function of phosphorylated p53 on centrosome and 
the molecular mechanism of signal transduction from impaired 
centrosomes to the nucleus remain unknown. Regarding the 
mechanism of p53 dissociation from centrosome, a study has 
revealed that Mortalin through binding to p53 facilitates dis-
sociation of p53 from centrosomes, which in turn results in 
release of the p53-mediated suppression of centrosome dupli-
cation (56). Interestingly, centrosome localization of Mortalin 
depends on the presence of centrosomal MPS1 kinase which 
is implicated in the regulation of centrosome duplication and 
FigURe 3 | Schematic diagram illustrating the complexity of Aurora-A–p53-mediated signaling in centrosome biogenesis.
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mitotic spindle checkpoint response (57). MPS1 phosphoryl-
ates Mortalin, which in turn hyperactivates MPS1 kinase in 
a feed-forward regulatory manner. Importantly, Mortalin 
phosphorylation-activated MPS1 can drive centrosome over-
duplication. Although MPS1 phosphorylation of p53 positively 
regulates postmitotic checkpoint response (20), the precise role 
of MPS1 in the regulation of p53 function at the centrosome 
remains uncertain. Interestingly, the promyelocytic leukemia 
gene 3 (PML3) was shown to physically interact with Aurora-A 
and inhibit its kinase activity, while loss of PML3 shown to 
increase Aurora-A kinase activity and reduced protein stability 
of p53 along with decreased p21 expression, leading to activa-
tion of Cdk2/Cyclin E activity (58). Therefore, since there is 
no direct evidence supporting a role of centrosome localized 
Aurora-A in centrosome duplication, it would be imperative 
to further investigate whether or not increased p53–Mortalin 
interaction mediated by Aurora-A promotes p53 dissociation 
from centrosome and accompanying reduction of serine 33 
phosphorylation is a cause of centrosome amplification induced 
in Aurora-A overexpressing cells.
At G1–S transition phase, Nucleophosmin/NPM1 is dis-
sociated from unduplicated centrosome and at G2 phase is 
again recruited to duplicated centrosome to activate Aurora-A 
through phosphorylation of serine 89 (59). Activated Aurora-A 
cooperates with PLK1 to produce the onset signal for entry into 
mitosis as well as centrosome maturation. Since PLK1 has been 
shown to induce p53 degradation through phosphorylation of 
Topors (60), Aurora-A–PLK1 functional interaction, therefore, 
could interfere with p53 function on the centrosome at G2/M 
phase. NPM1-activated Aurora-A has also shown to induce 
phosphorylation of Centrin 2 at serine170 for stabilization of the 
protein (61). Phosphorylation of CDC25B at serine 353, which 
in turn stabilizes MPS1, also leads to stabilization of Centrin 2 
through phosphorylation (62, 63). These findings indicate that 
Aurora-A and MPS1 cooperatively regulates Centrin 2 stability 
to induce centrosome maturation and separation. Activation of 
CDC25B is also pivotal for activation of Cdk1/Cyclin B, and a 
recent study has revealed that Cyclin B2 antagonizes p53 inhibi-
tory activity against Aurora-A to control proper timing of cen-
trosome separation at the onset of mitosis (64). Taken together, 
Aurora-A signaling branches off from CDC25B toward MPS1 
for control of Centrin 2 stabilization regulating centrosome 
activity and toward Cdk1/CyclinB for positive feedback toward 
activation of Aurora-A in part by preventing p53 inhibitory 
action on Aurora-A.
The studies mentioned above clearly present evidence in 
support of a critical role for p53 signaling in regulating cen-
trosome biogenesis and activity through cell cycle. In view of 
Aurora-A expression levels correlating with centrosome number 
and activity as well as known Aurora-A functional interactions 
with p53, Mortalin, PLK1, CDC25B, and, possibly MPS1, it 
will be interesting to investigate how the entire signaling axis 
FigURe 4 | Schematic illustration of Aurora-A–p73 interaction in spindle assembly checkpoint.
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involving these proteins maintains centrosomal homeostasis in 
proliferating cells.
AURORA-A–p73 iNTeRACTiON iN 
SPiNDLe ASSeMBLY CHeCKPOiNT
A number of studies have shown the association of deregulated 
Aurora-A expression and activity with SAC override in cells 
irrespective of the p53 functional status in cells. Therefore, it 
is currently unclear whether or not p53 is involved in Aurora-
A-mediated signal for SAC override. Accumulating evidence 
consistently suggest that p53 also functions in mitotic cell 
death and postmitotic checkpoint activated following aberrant 
mitosis and/or spindle damage through interaction with and 
phosphorylation by SAC proteins rather than being involved 
in  the  activation of SAC (20, 65–68). On the contrary, the 
role of Aurora-A–p73 interaction in SAC is relatively better 
defined. In vitro studies have shown roles of p73 in G2–M 
transition, mitotic exit, and mitotic cell death (69–72), while 
analysis of transgenic mouse lacking transactivation competent 
p73 (TAp73) revealed frequent occurrence of aberrant spindle 
structure associated with aneuploidy, chromosome instabil-
ity, and mitotic slippage with spindle poisons (26). Further 
biochemical studies have also shown interaction of TAp73 with 
SAC proteins BUB1, BUB3, and BUBR1, and this interaction 
is crucial for BUB1 and BUBR1 localization at kinetochores 
and BUBR1 kinase activity (26, 27). These results suggest 
that TAp73 is directly involved in regulating SAC pathway 
to maintain chromosome stability. More recent study has 
demonstrated that TAp73 interacts with the inhibitory mitotic 
checkpoint complex of MAD2 and CDC20, preventing activa-
tion of the E3 ubiquitin ligase APC/C, and that Aurora-A 
phosphorylation of TAp73 at serine 235 causes dissociation 
of the MAD2–CDC20 complex, facilitating mitotic exit (24), 
suggesting that Aurora-A–TAp73 interaction is essential for 
a critical step in the SAC inactivation pathway (Figure  4). 
Unlike its effect on MAD2–CDC20 interaction and p73 deple-
tion induced mislocalization of BUBR1 from the kinetochore, 
phosphorylation of p73 does not affect interaction of BUBR1 
with CDC20 and its kinetochore localization, indicating that 
p73 participates in distinct pathway to control SAC activa-
tion. Although serine 235 phosphorylation of p73 enhances its 
interaction with Mortalin as described above, a more detailed 
investigation on the role of Aurora-A–Mortalin signaling axis 
in mitotic progression and SAC is warranted.
Expression level of transactivation-defective ΔNp73 is known 
to be elevated in many tumors and ectopic expression of trans-
activation-defective ΔNp73 has been implicated in abnormal 
mitotic progression accompanied with multipolar spindle and 
cytokinesis failure resulting in multinucleated cells. However, 
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ΔNp73 neither affects SAC activation in the presence of spindle 
poison nor is it known to interact with BUBR1 (26, 73), indicat-
ing that expression of ΔNp73 helps bypass SAC. Intriguingly, 
Aurora-A also interacts with and phosphorylates ΔNp73 with 
similar efficacy as that of TAp73 but its phosphorylation site is 
different from TAp73 that remains to be mapped (24). Thus, 
characterization of physiological role of Aurora-A phosphoryl-
ated ΔNp73 could provide evidence of a novel signaling pathway 
affecting SAC.
AURORA-A–p53 SigNALiNg iN 
PLURiPOTeNT CeLLS
Aurora-A has been reported to suppresses p53 function via 
phosphorylation of cell-fate determinant protein NUMB. 
While NUMB interacts with and helps stabilize and activate 
the tumor suppressor protein p53 (74, 75), Aurora-A initiates 
a phosphorylation cascade of aPKC–PAR6–Lgl cell polarity 
complex that ultimately leads to NUMB phosphorylation dur-
ing mitosis to commit to asymmetric cell division (76–78). A 
recent study has revealed that phosphorylation of NUMB by 
Aurora–aPKC cascade disrupts its binding to p53 and promotes 
MDM2-mediated p53 degradation in cancer initiating cells of 
liver cancer (79). Thus, Aurora-A also antagonizes p53 activity 
indirectly through aPKC activation, resulting in maintenance of 
pluripotent state of cells and possibly promoting tumorigenesis. 
It would be interesting to examine if Aurora-A phosphoryla-
tion of p53 and NUMB synergistically affect disruption of their 
bindings.
A number of studies on cancer stem-like cells have revealed 
strong association of Aurora-A expression with gene expres-
sion of core stemness markers, such as Myc, Sox2, and Oct4. 
Additionally, Aurora-A–p53 functional interaction in the regu-
lation of self-renewal and differentiation of mouse embryonic 
stem cells (mESC) and somatic cell reprograming has also been 
investigated (80, 81). Loss-of-function screening for protein 
kinases and phosphatases essential in mESC development 
and subsequent functional studies revealed strong correlation 
between elevated expression of Aurora-A and the undifferenti-
ated state of mESC. Furthermore, loss of Aurora-A, but not loss 
of Aurora-A, mitotic substrates compromised self-renewal and 
triggered differentiation of mESC, indicating that non-canonical 
function of Aurora-A, unrelated to its role in mitosis, is pos-
sibly involved in regulating self-renewal potential of mESC 
(82). This observation also showed inverse correlation with 
p53 activity in mESC and attributed this finding to Aurora-A-
mediated inactivation of p53 function. The study also revealed 
that Aurora-A-mediated serine 215 phosphorylation rather than 
serine 315 phosphorylation is more critical in antagonizing p53-
induced mESC differentiation and p53-mediated suppression of 
induced Pluripotent Stem Cells (iPSC) reprograming via activa-
tion of gene expression program associated with pluripotency. 
Phosphorylation of serine 315, on the other hand, was shown to 
cause partial impairments of both mESC differentiation and sup-
pression of iPSC reprograming correlating with lower expression 
of pluripotency markers. The varying degree of downstream 
effects of the two Aurora-A-mediated p53 phosphorylated 
residues possibly represents stronger inhibition of p53 function 
following serine 215 phosphorylation resulting in complete loss 
of its transactivation activity and cytoplasmic sequestration 
reflecting the naturally observed localization of endogenous 
p53 in mESC (83). The study concluded that Aurora-A controls 
pluripotency through inhibition of p53 target gene expression 
required for ectodermal and mesodermal differentiation. The 
observation regarding serine 315 phosphorylation showing less 
pronounced phenotype in this study appeared conflicting to an 
earlier report showing elevated serine 315 phosphorylation dur-
ing mESC differentiation and knockin of serine 315 phosphor-
deficient mutant impairing mESC differentiation. Importantly, 
serine 315 phosphorylation was also reported to enable the 
recruitment of the corepressor mSin3a to the NANOG promo-
tor, resulting in complete suppression of NANOG transcription 
and primitive endodermal differentiation (84–86). Serine 315 
phosphorylation is known to be mediated not only by Aurora-A 
but also by Cdk/cyclin complex. In view of the observed loss 
of serine 33 phosphorylation in serine 215 phosphorylated p53, 
it is plausible that serine 215 phosphorylation might inhibit 
serine 315 phosphorylation by Cdk1 or Aurora-A. Alternatively, 
Aurora-A phosphorylation of the two p53 residues may be play-
ing non-overlapping physiological roles in Aurora-A-mediated 
cellular processes.
In contrast to the requirement of Aurora-A in maintenance 
of pluripotency and induction of iPSC state mentioned above, 
a study reported that loss of Aurora-A function is essential for 
somatic cell reprograming (87). In this study, authors reported 
that loss of Aurora-A function following small-molecule inhibi-
tor treatment or siRNA knockdown enhanced efficacy of iPSC 
generation with cells reaching a fully reprogramed state. The iPSC 
generated by this approach possessed ability to differentiate into 
different lineages in vitro and in vivo. Moreover, p53 depletion 
could further enhance the effect of loss of Aurora-A function. 
The underlying reasons for these contradictory findings are not 
known at this time and need to be investigated.
geNeTiCALLY eNgiNeeReD  
AURORA-A–p53 TARgeTeD 
MOUSe MODeLS
Comprehensive genomic analyses have identified Aurora-A as a 
low penetrance tumor-susceptibility gene and elevated expression 
was reported to play an essential pathological in tumor develop-
ment correlating with prognosis and resistance to therapy (80, 
88–91). Several transgenic mouse models have been developed 
to gain direct evidence of Aurora-A tumorigenic potential and 
associated phenotypic alternations in  vivo, which have yielded 
somewhat conflicting and distinct results (92–94). While Wap-
Cre mouse model system in which Aurora-A was constitutively 
overexpressed under CAG-CAT promoter in mammary gland 
after one cycle of pregnancy developed hyperplasia in p53 wild-
type background and precancerous atypical ductal hyperplasia in 
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p53–null background (92, 94), MMTV promoter-driven mouse 
model was reported to develop mammary tumors in both p53 
wild-type and heterozygous background after four to five cycles 
of pregnancy (93). Notably, centrosome amplification and chro-
mosome instability were detected in all mouse models, suggesting 
that Aurora-A overexpression affects p53 function in the main-
tenance of centrosome homeostasis and chromosomal stability 
in vivo. Consistent with in vitro studies, activation of AKT signal-
ing pathway leading to Cyclin D overexpression was seen in the 
tumors developed in MMTV–Aurora-A mice. We have recently 
reported a mammary gland targeted Aurora-A mouse model in 
a p53 wild-type background in which Aurora-A expression is 
driven by ovine β-lactoglobulin promoter led to the development 
of mammary tumors after four to five of pregnancy cycles (95). In 
addition to genomic instability, reduced expression of p53 protein 
and activation of AKT signal pathway was detected in tumors 
similar to MMTV–Aurora-A mouse model, again suggesting 
that elevated levels of Aurora-A can be oncogenic with inhibitory 
effects on p53-mediated tumor suppressor signaling pathways. 
It is relevant to mention, in this context, that an inducible gene 
switch mouse model overexpressing Aurora-A in skin epidermis 
exposed to tumor promoter 12-O-tetradecanoylphorbol 13-ace-
tate (TPA) and the mutagen 7,12-dimethylbenz(a)anthracene, 
developed by us earlier, revealed malignant progression of skin 
tumors with centrosome amplification, abnormal spindle forma-
tion, and genomic instability (96). Expression of p53 protein was 
lost, and amplification of MDM2 gene was concurrently found in 
these tumors. Taken together, Aurora-A overexpressing mouse 
models of organ-specific tumors have revealed loss of p53 expres-
sion recapitulating naturally occurring Aurora-A and p53 expres-
sion changes seen in human tumors. Further in-depth studies to 
elucidate the role of Aurora-A–p53 signaling cascades relevant 
to human tumor development utilizing Aurora-A overexpressing 
mouse models are warranted.
CONCLUSiON
Functional interactions between Aurora kinases and p53 fam-
ily proteins coordinately regulate diverse cellular pathways by 
modulating activity and subcellular localization of each other 
and their downstream effector proteins. Deregulations of these 
interactions in cells undergoing tumorigenic transformation 
have significant functional consequences on induction of chro-
mosome instability, development of different tumor-associated 
phenotypes including resistance to therapy. In addition to Aurora 
kinase functional interactions with wild-type p53 and p73, there 
is evidence of Aurora-A interacting with and phosphorylating 
mutant p53 protein. Physiological function of Aurora-A–mutant 
p53 interactions have not been elucidated yet. Mutant p53 and 
transactivation-deficient mutant of p73 also phenocopy some 
of the Aurora-A overexpression-induced phenotypes. It would 
be interesting to investigate the functional consequences of 
Aurora-A phosphorylation of mutant p53 family members in the 
p53 signaling cascades and their significance in the development 
of tumorigenic phenotypes.
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